Miyoshi myopathy and limb girdle muscular dystrophy R2 are the same disease.


Journal

Neuromuscular disorders : NMD
ISSN: 1873-2364
Titre abrégé: Neuromuscul Disord
Pays: England
ID NLM: 9111470

Informations de publication

Date de publication:
04 2021
Historique:
received: 12 11 2020
revised: 13 01 2021
accepted: 18 01 2021
pubmed: 22 2 2021
medline: 19 11 2021
entrez: 21 2 2021
Statut: ppublish

Résumé

This study aims to determine clinically relevant phenotypic differences between the two most common phenotypic classifications in dysferlinopathy, limb girdle muscular dystrophy R2 (LGMDR2) and Miyoshi myopathy (MMD1). LGMDR2 and MMD1 are reported to involve different muscles, with LGMDR2 showing predominant limb girdle weakness and MMD1 showing predominant distal lower limb weakness. We used heatmaps, regression analysis and principle component analysis of functional and Magnetic Resonance Imaging data to perform a cross-sectional review of the pattern of muscle involvement in 168 patients from the Jain Foundation's international Clinical Outcomes Study for Dysferlinopathy. We demonstrated that there is no clinically relevant difference in proximal vs distal involvement between diagnosis. There is a continuum of distal involvement at any given degree of proximal involvement and patients do not fall into discrete distally or proximally affected groups. There appeared to be geographical preference for a particular diagnosis, with MMD1 being more common in Japan and LGMDR2 in Europe and the USA. We conclude that the dysferlinopathies do not form two distinct phenotypic groups and therefore should not be split into separate cohorts of LGMDR2 and MM for the purposes of clinical management, enrolment in clinical trials or access to subsequent treatments.

Identifiants

pubmed: 33610434
pii: S0960-8966(21)00010-9
doi: 10.1016/j.nmd.2021.01.009
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

265-280

Subventions

Organisme : Medical Research Council
ID : MR/S005021/1
Pays : United Kingdom

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Auteurs

Ursula Moore (U)

The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Central Parkway, Newcastle upon Tyne, United Kingdom.

Heather Gordish (H)

Center for Translational Science, Division of Biostatistics and Study Methodology, Children's National Health System, Washington, DC, United States; Pediatrics, Epidemiology and Biostatistics, George Washington University, Washington, DC, United States.

Jordi Diaz-Manera (J)

Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Barcelona, Spain; Neuromuscular Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau.

Meredith K James (MK)

The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Central Parkway, Newcastle upon Tyne, United Kingdom.

Anna G Mayhew (AG)

The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Central Parkway, Newcastle upon Tyne, United Kingdom.

Michela Guglieri (M)

The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Central Parkway, Newcastle upon Tyne, United Kingdom.

Roberto Fernandez-Torron (R)

The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Central Parkway, Newcastle upon Tyne, United Kingdom.

Laura E Rufibach (LE)

The Jain Foundation, Seattle, Washington DC, United States.

Jia Feng (J)

Center for Translational Science, Division of Biostatistics and Study Methodology, Children's National Health System, Washington, DC, United States.

Andrew M Blamire (AM)

Magnetic Resonance Centre, Translational and Clinical Research Institute, Newcastle University, United Kingdom.

Pierre G Carlier (PG)

AIM & CEA NMR Laboratory, Institute of Myology, Pitié-Salpêtrière University Hospital, 47-83 Paris, France.

Simone Spuler (S)

Charite Muscle Research Unit, Experimental and Clinical Research Center, a Joint Cooperation of the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine, Berlin, Germany.

John W Day (JW)

Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, United States.

Kristi J Jones (KJ)

The Children's Hospital at Westmead, and The University of Sydney, Australia.

Diana X Bharucha-Goebel (DX)

Department of Neurology Children's National Health System, Washington, DC, United States; National Institutes of Health (NINDS), Bethesda, MD, United States.

Emmanuelle Salort-Campana (E)

Service des maladies neuromusculaire et de la SLA, Hôpital de La Timone, Marseille, France.

Alan Pestronk (A)

Department of Neurology Washington University School of Medicine, St. Louis, MO, United States.

Maggie C Walter (MC)

Friedrich-Baur-Institute, Department of Neurology, Ludwig-Maximilians-University of Munich, Germany.

Carmen Paradas (C)

Neuromuscular Unit, Department of Neurology, Hospital U. Virgen del Rocío/Instituto de Biomedicina de Sevilla, Sevilla, Spain.

Tanya Stojkovic (T)

Centre de référence des maladies neuromusculaires, Institut de Myologie, AP-HP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France.

Madoka Mori-Yoshimura (M)

Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry Tokyo, Japan.

Elena Bravver (E)

Neuroscience Institute, Carolinas Neuromuscular/ALS-MDA Center, Carolinas HealthCare System, Charlotte, NC, United States.

Elena Pegoraro (E)

Department of Neuroscience, University of Padova, Italy.

Linda Pax Lowes (LP)

The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH United States.

Jerry R Mendell (JR)

The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH United States.

Kate Bushby (K)

The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Central Parkway, Newcastle upon Tyne, United Kingdom.

Volker Straub (V)

The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Central Parkway, Newcastle upon Tyne, United Kingdom. Electronic address: Volker.straub@newcastle.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH